You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Retargeting FDA Approved Anticancer Liposomal Drugs to Cancer Stem Cells
SBC: ZoneOne Pharma Topic: ODESCRIPTION provided by applicant The goal of this research is to develop a ligand product and facile method to use it to target FDA approved liposomal anticancer drugs to cancer stem cells that overexpress CD We have devised a highly efficient chemo enzymatic synthesis of a hyaluronan lipid HA lipid ligand and have teamed with ZoneOne Pharma to develop a simple and robust micelle transfer ...
STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health -
Breath ammonia monitoring device for children with urea cycle disorders
SBC: Lumina Diagnostics, Inc. Topic: NICHDDESCRIPTION provided by applicant We propose to develop a non invasive device to enable children with urea cycle disorders and their parents guardians and physicians to actively manage the disorder at home and improve outcomes in the clinic Urea cycle disorders UCD are inborn errors of metabolism that impair oneandapos s ability to convert ammonia NH a neurotoxin into urea which is ...
STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health -
USE OF DNATrax TO MODEL THE TRANSPORT OF PARTICULATE MATTER IN URBAN ENVIRONMENTS
SBC: DNATREK, LLC Topic: NIEHSDESCRIPTION provided by applicant Science based strategies for quantifying and mitigating the impact of anthropogenic emissions on public health are essential for the sustainability of cities Similar strategies can also be used to develop and assess the effectiveness of a national defense system against terrorist attacks with airborne biological agents and protect against the spread of airborn ...
STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health -
A biochemical companion diagnostic platform to measure kinase inhibitor pharmacodynamics in leukemia
SBC: MICROFLUIDIC INNOVATIONS, LLC Topic: 102DESCRIPTION provided by applicant Kinase inhibitors created a new paradigm in chemotherapy and are a major focus of new oncology drug development The Bcr Abl inhibitor imatinib was a breakthrough drug for chronic myelogenous leukemia with overwhelming early results however at least of patients are either intolerant resistant or experience recurrence within years and individual respo ...
STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health -
Developing efficient and safe cell-permeable reprogramming peptides for generation of iPS cells.
SBC: Vivoscript, Inc. Topic: 200DESCRIPTION provided by applicant The groundbreaking discovery of induced pluripotent stem cells iPSCs has opened a new page for developing personalized cell based therapies against various devastating human diseases without ethical concerns of using human embryonic stem cells However the future clinical applications of iPSCs remain in doubt due to potential risks of undesired genomic alter ...
STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health -
Optimizing HaploSeq for whole-genome phased haplotypes in biomedical applications
SBC: ARIMA GENOMICS, INC. Topic: 172DESCRIPTION provided by applicant Phenomenal advances in DNA sequencing technologies have enabled systematic identification of genetic variants in human individuals and the recent FDA marketing authorization of the first next generation genome sequencer signals the arrival of a new era of pharmacogenomics and personalized medicine Nevertheless DNA sequencing alone fails to provide complete i ...
STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health -
Development of Therapeutics to Treat Candida albicans Biofilm Infections
SBC: BIOSYNESIS, INC. Topic: NIAIDDESCRIPTION provided by applicant The yeast Candida albicans is a normal resident of the human digestive tract It is also the most common fungal pathogen of humans causing both mucosal and systemic infections particularly in immune compromised individuals The majority of new C albicans infections arise from the presence of persistent C albicans cells existing in a biofilm These biofilm b ...
STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health -
Rapid Diagnostics for Mucormycosis
SBC: VITALEX BIOSCIENCES LLC Topic: NIAIDDESCRIPTION provided by applicant Mucormycosis most commonly caused by Rhizopus oryzae is a life threatening infection that occurs in patients immunocompromised by diabetic ketoacidosis DKA neutropenia corticosteroid use and or increased serum iron Because of the rising prevalence of these risk factors the incidence of mucormycosis has risen Despite disfiguring surgery and aggressive ...
STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health -
A high-throughput kit for detection of RNA modifications
SBC: MAVERIX BIOMICS, INC. Topic: NIDADESCRIPTION provided by applicant The broad objective of this project is to develop an integrated wet lab dry lab kit for high throughput detection of RNA modifications The final product will provide all required molecular biology reagents a set of simple and robust experimental manipulations for facile analysis of modifications and researcher friendly analytic cloud based software requi ...
STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health -
A Protective Tetravalent Vaccine Candidate for Dengue Fever Virus
SBC: ALTRAVAX, INC Topic: NIAIDDESCRIPTION provided by applicant There are approximately million cases of dengue fever each year with billion people at risk mostly in low income countries There are four serotypes of dengue fever virus DENV and in its uncomplicated form the disease is worthy of its indigenous name andquot break bone feverandquot An individual may suffer sequential infections with multiple DE ...
STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health